Skip to content
drillr.ai
Sign up

AZN

AstraZeneca PLC

NYSE · Healthcare · Drug Manufacturers - General · GB

$161.57
−1.95%
Ask drillr

  • Sep 2, 2026, 14:21 UTC

    AstraZeneca announced positive results from its SANOVO Phase III trial, showing that Tagrisso plus Orpathys improved progression-free survival in first-line EGFR-mutated non-small cell lung cancer.

    Source:

  • Sep 1, 2026, 06:05 UTC

    AstraZeneca completed its acquisition agreement for ZEGFROVY.

    Source:

  • Aug 31, 2026, 00:34 UTC

    Hutchison China MediTech announced positive topline results from the SANOVO China Phase III study of savolitinib (ORPATHYS) plus osimertinib (TAGRISSO) in EGFR-mutant MET-overexpressing non-small cell lung cancer, showing statistically significant progression-free survival improvement.

    Source:

  • Aug 28, 2026, 09:23 UTC

    AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.

    Source:

  • Aug 27, 2026, 06:00 UTC

    Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE (tezepelumab-ekko) in patients with eosinophilic esophagitis, showing statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints through week 52.

    Source:

  • Aug 26, 2026, 03:20 UTC

    Sinopharm Holding and AstraZeneca launched a special cooperation project on essential medicines in Shanghai, deepening their strategic partnership in pharmaceutical distribution and grassroots healthcare accessibility.

    Source:

  • Aug 25, 2026, 06:52 UTC

    AstraZeneca PLC priced a €2.55 billion euro bond offering across four tranches, issued by its subsidiary AstraZeneca Finance LLC with a parent guarantee, for general corporate purposes.

    Source:

  • Aug 24, 2026, 12:30 UTC

    The FTSE 100 rose 13 points to 10,830 by midday on 24 August 2026, led by miners and travel stocks, while the FTSE 250 slipped 0.1% to 24,703.

    Source:

  • Aug 24, 2026, 07:45 UTC

    The FTSE 100 index opened flat, easing 0.06% to 10,810, with AstraZeneca falling about 1% and FirstGroup dropping as much as 7% before recovering.

    Source:

  • Aug 21, 2026, 09:30 UTC

    AstraZeneca shares lost 0.86% to 11,984p on August 21, 2026.

    Source:

  • Aug 20, 2026, 10:04 UTC

    Ingrid Zhang, Chief Commercial Officer International at Novartis, decided to leave the company to pursue external opportunities, announced via an internal memo on August 19, 2026.

    Source:

  • Aug 20, 2026, 08:55 UTC

    AstraZeneca's Ravulizumab received approval in China for a third indication, treating paroxysmal nocturnal hemoglobinuria (PNH), as shown on the NMPA website.

    Source:

  • Aug 18, 2026, 12:23 UTC

    On August 18, 2026, Yingte Group and Hangzhou PICC signed a strategic cooperation agreement to jointly launch a provincial exclusive specialty drug commercial insurance product called 'Yingte-PICC Yao Kangbao'.

    Source:

  • Aug 17, 2026, 22:00 UTC

    The UK government announced on August 12 that it is investing 22 million pounds, including 20 million pounds for a new Pre-clinical Translational Models Hub in Cambridge, to grow miniature human organs from NHS patients' cells for drug testing.

    Source:

  • Aug 17, 2026, 13:22 UTC

    AstraZeneca discontinued a late-stage trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer patients lacking PD-L1, following a data monitoring committee recommendation.

    Source:

  • Aug 17, 2026, 07:09 UTC

    AstraZeneca reported that its Enhertu treatment showed meaningful improvement in delaying disease progression in non-small cell lung cancer and would advance to phase three.

    Source:

  • Aug 17, 2026, 06:28 UTC

    AstraZeneca announced on Monday that it is discontinuing a late-stage trial testing volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer.

    Source:

  • Aug 17, 2026, 06:19 UTC

    AstraZeneca announced the official launch of Tezspire (tezepelumab) in China on August 17, 2026.

    Source:

  • Aug 10, 2026, 15:00 UTC

    A London-based drugmaker (AstraZeneca) announced plans to invest US$30 billion in U.S. research and development and supply chain infrastructure over five years.

    Source:

  • Aug 7, 2026, 09:15 UTC

    Fresnillo surged 2.74% to 2,813p, Convatec Group advanced 2.73% to 233p, BAE Systems climbed 1.68% to 2,237p, London Stock Exchange Group gained 1.53% to 8,884p, Diageo rose 1.47% to 1,758p, and AstraZeneca added 1.38% to 12,014p.

    Source:

  • Aug 6, 2026, 10:15 UTC

    Tlwm acquired a new position in Astrazeneca Plc during the second quarter, purchasing 9,279 shares valued at approximately $1.76 million.

    Source:

  • Aug 5, 2026, 23:01 UTC

    The UK government expanded its fast-track research visa program, allowing over 100 UK companies including AstraZeneca and Jaguar Land Rover to bring in workers, aiming to capitalize on US President Donald Trump's immigration crackdown.

    Source:

  • Aug 5, 2026, 14:01 UTC

    AstraZeneca shares rose about 6% on Wednesday after Reuters reported there are no merger discussions with Bristol Myers Squibb, easing investor concerns.

    Source:

  • Aug 5, 2026, 09:51 UTC

    CSPC Group received a US$10 million milestone payment from AstraZeneca on 5 August 2026 under the strategic research and development collaboration agreement, related to AstraZeneca's exercise of the license option for one of the PCC projects.

    Source:

  • Aug 5, 2026, 08:35 UTC

    CSPC Group and AstraZeneca signed a joint venture contract to establish a joint venture.

    Source:

  • Aug 4, 2026, 10:15 UTC

    SOPHiA GENETICS announced a global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies.

    Source:

  • Aug 3, 2026, 12:00 UTC

    AstraZeneca Plc shares opened at $169.77 on Monday, trading up 0.1%.

    Source:

  • Aug 3, 2026, 10:09 UTC

    AstraZeneca announced the official launch of its innovative drug Imjudo (tremelimumab) in China, for use in combination with Imfinzi (durvalumab) as first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma.

    Source:

  • Aug 2, 2026, 19:36 UTC

    AstraZeneca has held talks with Bristol Myers Squibb about a potential merger, as reported by the Financial Times on Sunday.

    Source:

  • Jul 27, 2026, 11:51 UTC

    MegaStone Biologics received a full upfront payment of $420 million from AstraZeneca on May 29, 2026, and recognized part of it as revenue.

    Source:
Page 1Next →